Newsroom | 5768 results
Sorted by: Latest
-
Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 30,330 common shares of the Company (the "Options") with effective grant dates of July 20, 2026....
-
The Vessyl Opens in Costa Rica as the World's First 4D Sound Wellness Resort
LA FORTUNA, Costa Rica--(BUSINESS WIRE)--As burnout, digital overload and constant distraction become defining challenges of modern life, a new kind of wellness destination has opened in Costa Rica- one designed not to help people escape the world, but to reconnect with it. Set on 118 acres of rainforest beneath the iconic Arenal Volcano, The Vessyl is the world's first 4D Sound Wellness Resort, introducing a new category of immersive hospitality centered on personalized transformation, nervous...
-
Clinigen Appoints Greg Skalicky as Chief Executive Officer
LONDON--(BUSINESS WIRE)--Clinigen, the global pharmaceutical services company, today announced the appointment of Greg Skalicky as Group Chief Executive Officer....
-
Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced its Chief Accounting Officer, Irene Becklund will depart the company after more than seven years, effective October 9, 2026. Becklund will then serve as an advisor to the company for several months to assist with the transition. The company will conduct a search for her permanent successor, with Yemi Okupe, CFO of Hims & Hers, assuming the responsibilities of...
-
New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders, today announced results from a new healthcare claims study of treatment patterns of newly diagnosed and established GAD patients, including pharmacotherapy use, discontinuation, switching and treatment progression. The fi...
-
Curaleaf Launches Free CPD-Accredited Platform to Close Medical Cannabis Training Gap for UK Healthcare Professionals
LONDON--(BUSINESS WIRE)--Curaleaf International, one of the global leaders in medical cannabis, announces the launch of the Curaleaf Education Platform, providing access to CPD-accredited medical cannabis training for healthcare professionals across the UK. A Curaleaf survey of UK GPs found that just 4% had received any formal education on medical cannabis, and 81% described their understanding of it as limited or non-existent, with 55% saying they would need to better understand medical cannab...
-
Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the 26-week results (Part B) from its second ongoing Phase 3 COMP006 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD) which confirm COMP360’s rapid onset and durable profile. The 26-week findings in nearly 600 patients build on previously reported resul...
-
Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to eight newly hired non-executive employees consisting of options to purchase an aggregate of 169,740 common shares of the Company (the "Options") with effective grant dates of July 6, 2026...
-
Country Life, LLC Acquires Aura Cacia, Strengthening Its Commitment to Holistic Wellness
HAUPPAUGE, N.Y.--(BUSINESS WIRE)--Country Life, LLC acquires Aura Cacia®, creating a more comprehensive wellness offering for consumers...
-
AdvoCare® Activates at FC Dallas World Cup Watch Parties in Frisco
RICHARDSON, Texas--(BUSINESS WIRE)--AdvoCare International, LLC is proud to announce its participation in the FC Dallas Soccer Celebration Watch Parties taking place throughout the 2026 FIFA World Cup™. From June 11 through July 19, AdvoCare will host interactive activation stations each weekend at Simpson Plaza in Frisco, engaging fans as the global tournament unfolds across North America.Dallas is one of the premier host cities for the 2026 FIFA World Cup™, with nine official matches scheduled...